Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other weight ...

The Ipsos survey of 1,078 adults found 24% of people would use weight-loss jabs if they were provided for free by the health ...

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a ...

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to stay safe before surgeries ...

Share on Pinterest LeoPatrizi/Getty Images Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus. Currently, only Wegovy is approved for weight loss in the United States.

A surprise amount of Brits say they would take anti-obesity drugs if they were given to them for free on the ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other weight loss fads and trends, people gain the weight back after they stop taking the drug. One recent study ...